Reviews

• Reviews Home

Aethlon's study shows 92% HIV load reduction

Date: 2009-03-14 00:53:36 Member: Manoj Karwa Category: Research Discipline: Clinical / Health / Medicine Link: http://www.biospectrumasia.com/Content/120309IND8842.asp?nl=3_18453_Mar12

Bangalore, Mar 12, 2009: Aethlon Medical, a manufacturer of diagnostic and therapeutic filtration devices, announced results of the 'first-in-man' study of the Aethlon Hemopurifier to treat Human Immunodeficiency Virus (HIV), which causes AIDS. In the study, viral load was reduced by 92 percent in an HIV-infected individual who received a total of twelve Hemopurifier treatments administered thrice weekly over the span of one month.

The study, which was conducted in the absence of any antiviral drug therapy, documented initial viral load of 102,759 iu/ml being reduced to 7,960 iu/ml at the conclusion of the study. The study, which was conducted at the Sigma New Life Hospital in Punjab, India, was designed to provide insight that will define future clinical programs and commercialization pathways for the Aethlon Hemopurifier.

The Hemopurifier is a therapeutic filtration device that serves as an artificial adjunct to the immune system. In HIV care the Hemopurifier targets the clearance of all circulating strains of infectious HIV, including varieties that cause patients to fail antiviral drug regimens. Additionally, the device assists to preserve the immune response through the removal of gp120 and other toxic proteins that shed from HIV to kill-off immune cells, the hallmark of AIDS. Beyond HIV care, the company release says, Hemopurifier is a leading broad-spectrum treatment candidate against drug and vaccine resistant viral pathogens.

“Our first HIV treatment experience supports the vision of our Hemopurifier becoming a primary strategy to inhibit disease progression once an individual becomes resistant to antiviral drugs,” said Aethlon Chairman and CEO, Mr Jim Joyce. “Additionally, our device offers a synergistic mechanism of action that could enhance and extend the benefit of both established and candidate antiviral therapies.”

Based on previous treatment outcomes in Hepatitis-C (HCV) infected patients, Aethlon believes the Hemopurifier to be the first therapeutic candidate to demonstrate meaningful viral load reductions in both HIV and HCV infected individuals. According to the Centers for Disease Control and Infection (CDC), about one quarter of HIV-infected persons are also infected with HCV. HCV is one of the most important causes of chronic liver disease and HCV infection progresses more rapidly to liver damage in HIV-infected persons.

Comments (0)

Vote (2)